These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38464223)

  • 1. Heparin-enriched plasma proteome is significantly altered in Alzheimer's Disease.
    Guo Q; Ping L; Dammer EB; Yin L; Xu K; Shantaraman A; Fox EJ; Golde TE; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT
    Res Sq; 2024 Feb; ():. PubMed ID: 38464223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease.
    Wang H; Dey KK; Chen PC; Li Y; Niu M; Cho JH; Wang X; Bai B; Jiao Y; Chepyala SR; Haroutunian V; Zhang B; Beach TG; Peng J
    Mol Neurodegener; 2020 Jul; 15(1):43. PubMed ID: 32711556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease.
    Modeste ES; Ping L; Watson CM; Duong DM; Dammer EB; Johnson ECB; Roberts BR; Lah JJ; Levey AI; Seyfried NT
    Mol Neurodegener; 2023 Jul; 18(1):48. PubMed ID: 37468915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease.
    Zhou M; Haque RU; Dammer EB; Duong DM; Ping L; Johnson ECB; Lah JJ; Levey AI; Seyfried NT
    Clin Proteomics; 2020; 17():19. PubMed ID: 32514259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic Changes in the Human Cerebrovasculature in Alzheimer's Disease and Related Tauopathies Linked to Peripheral Biomarkers in Plasma and Cerebrospinal Fluid.
    Wojtas AM; Dammer EB; Guo Q; Ping L; Shantaraman A; Duong DM; Yin L; Fox EJ; Seifar F; Lee EB; Johnson ECB; Lah JJ; Levey AI; Levites Y; Rangaraju S; Golde TE; Seyfried NT
    medRxiv; 2024 Jan; ():. PubMed ID: 38260316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting Detergent-Insoluble Proteome in Alzheimer's Disease by TMTc-Corrected Quantitative Mass Spectrometry.
    Zaman M; Fu Y; Chen PC; Sun H; Yang S; Wu Z; Wang Z; Poudel S; Serrano GE; Beach TG; Li L; Wang X; Peng J
    Mol Cell Proteomics; 2023 Aug; 22(8):100608. PubMed ID: 37356496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic Network Analysis of Alzheimer's Disease Cerebrospinal Fluid Reveals Alterations Associated with
    Dammer EB; Shantaraman A; Ping L; Duong DM; Gerasimov ES; Ravindran SP; Gudmundsdottir V; Frick EA; Gomez GT; Walker KA; Emilsson V; Jennings LL; Gudnason V; Western D; Cruchaga C; Lah JJ; Wingo TS; Wingo AP; Seyfried NT; Levey AI; Johnson ECB
    medRxiv; 2023 Oct; ():. PubMed ID: 37961720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.
    Dammer EB; Ping L; Duong DM; Modeste ES; Seyfried NT; Lah JJ; Levey AI; Johnson ECB
    Alzheimers Res Ther; 2022 Nov; 14(1):174. PubMed ID: 36384809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome.
    Drummond E; Kavanagh T; Pires G; Marta-Ariza M; Kanshin E; Nayak S; Faustin A; Berdah V; Ueberheide B; Wisniewski T
    Acta Neuropathol Commun; 2022 Apr; 10(1):53. PubMed ID: 35418158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic changes in the human cerebrovasculature in Alzheimer's disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluid.
    Wojtas AM; Dammer EB; Guo Q; Ping L; Shantaraman A; Duong DM; Yin L; Fox EJ; Seifar F; Lee EB; Johnson ECB; Lah JJ; Levey AI; Levites Y; Rangaraju S; Golde TE; Seyfried NT
    Alzheimers Dement; 2024 Jun; 20(6):4043-4065. PubMed ID: 38713744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review.
    Wesenhagen KEJ; Teunissen CE; Visser PJ; Tijms BM
    Crit Rev Clin Lab Sci; 2020 Mar; 57(2):86-98. PubMed ID: 31694431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic Profiling of Plasma and Brain Tissue from Alzheimer's Disease Patients Reveals Candidate Network of Plasma Biomarkers.
    Chen M; Xia W
    J Alzheimers Dis; 2020; 76(1):349-368. PubMed ID: 32474469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer's Disease.
    Watson CM; Dammer EB; Ping L; Duong DM; Modeste E; Carter EK; Johnson ECB; Levey AI; Lah JJ; Roberts BR; Seyfried NT
    Sci Data; 2023 May; 10(1):261. PubMed ID: 37160957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.
    Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM;
    Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease.
    van der Ende EL; In 't Veld SGJG; Hanskamp I; van der Lee S; Dijkstra JIR; Hok-A-Hin YS; Blujdea ER; van Swieten JC; Irwin DJ; Chen-Plotkin A; Hu WT; Lemstra AW; Pijnenburg YAL; van der Flier WM; Del Campo M; Teunissen CE; Vermunt L
    Brain; 2023 Nov; 146(11):4495-4507. PubMed ID: 37348871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease.
    Bonham LW; Desikan RS; Yokoyama JS;
    Acta Neuropathol Commun; 2016 Jun; 4(1):65. PubMed ID: 27357286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.